NCT05794451

Brief Summary

Alzheimer's disease dementia (AD) is a debilitating and prevalent neurodegenerative disease in older adults globally. Cognitive impairment, a hallmark of AD, is assessed through verbal tests that require high specialization, and while accepted as screening tools for AD, general practitioners seldom use them. AD can be diagnosed with expensive, invasive neuroimaging and blood tests, but these are usually conducted when cognitive functioning is already severely impaired. Thus, finding a novel, non-invasive tool to detect and differentiate mild cognitive impairment (MCI) and AD is a prime public health interest. Self-figure drawings (a projective tool in which individuals are asked to draw a picture of themselves), are easy to administer and have been shown to differentiate between healthy and cognitively impaired individuals, including AD. Convolutional Neural Network (CNN) (a type of deep neural network, applied to analyze visual imagery) has advanced to assess health conditions using art products. Therefore, the proposed study suggests utilizing CNN-based methods to develop and test an application tailored to differentiate between drawings of individuals with MCI, AD, and healthy controls (HC) using 4,000 self-figure drawings. This

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,413

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 20, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

March 20, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 3, 2023

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

May 4, 2026

Status Verified

April 1, 2026

Enrollment Period

2.8 years

First QC Date

March 20, 2023

Last Update Submit

April 28, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Cognition

    The Montreal Cognitive Assessment (MoCA) is a 10-minute paper-based test that aims to detect MCI in older patients with symptomatology, suggesting impaired cognition. The MoCA is composed of 12 tasks to detect short-term memory, visuospatial ability, executive functioning, phonemic fluency, abstraction, attention, concentration, working memory, language, and orientation.

    One day

  • Cognition for adults diagnosed with Alzheimer's disease

    The Self-reported Cognitive Difficulties (CDS)75 is a 39-item questionnaire that requires participants or their caregivers in case of AD to rate how often they currently experience cognitive difficulties in everyday life using a 5-point scale (0 -"never" to 4 -"very often").

    One day

  • Self-figure drawing -Cognition

    Self-figure drawing. Participants will be asked to draw themselves using a pencil on an A4-sized sheet of paper.

    One day

Study Arms (3)

Healthy controls

Adults aged 60 and above without cognitive impairment

Mild cognitive impairment

Adults 60 and above with mild cognitive impairment

Alzheimer's disease

Adults diagnosed with Alzheimer's disease

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults aged 60 or above, who live in Israel.

You may qualify if:

  • Adults aged 60 and above with subtle signs of risk of future cognitive decline, residing in the community or in nursing homes with a minimum of 10 years of education.

You may not qualify if:

  • Current or past psychiatric illness, the presence of congenital/organic cognitive condition, severe visual or motor impairment, and terminal illness (to avoid the effect of comorbidities).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Haifa

Haifa, Israel

Location

MeSH Terms

Conditions

Alzheimer DiseaseCognitive Dysfunction

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersCognition Disorders

Study Officials

  • Johanna Czamanski-Cohen, PhD

    University of Haifa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Lecturer

Study Record Dates

First Submitted

March 20, 2023

First Posted

April 3, 2023

Study Start

March 20, 2023

Primary Completion

December 31, 2025

Study Completion

March 31, 2026

Last Updated

May 4, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

This is an artificial intelligence study, thus there will not be a dataset available for sharing.

Locations